28438506|t|Diacylglycerol Kinase ζ Limits Cytokine -dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity
28438506|a|Interleukin-2 and -15 drive expansion / differentiation of cytotoxic CD8(+) T cells that eliminate targets via antigen-independent killing. This property is clinically relevant for the improvement of T cell -based antitumor therapies. Diacylglycerol kinase α and ζ (DGKα / ζ) metabolize the diacylglycerol generated following antigen recognition by T lymphocytes. Enhanced expression of these two lipid kinases in tumor-infiltrating CD8(+) T cells promotes a hyporesponsive state that contributes to tumor immune escape. Inhibition of these two enzymes might thus be of interest for potentiating conventional antigen -directed tumor elimination. In this study, we sought to characterize the contribution of DGKα and ζ to antigen -independent cytotoxic functions of CD8(+) T cells. Analysis of DGKζ - deficient mice showed an increase in bystander memory -like CD8(+) T cell populations not observed in DGKα - deficient mice. We demonstrate that DGKζ limits cytokine responses in an antigen -independent manner. Cytokine -specific expansion of DGKζ - deficient CD8(+) T cells promoted enhanced differentiation of innate-like cytotoxic cells in vitro, and correlated with the more potent in vivo anti-tumor responses of DGKζ - deficient mice engrafted with the murine A20 lymphoma. Our studies reveal a isoform - specific function for DGKζ downstream of IL-2 / IL-15 -mediated expansion of innate-like cytotoxic T cells, Pharmacological manipulation of DGKζ activity is of therapeutic interest for cytokine -directed anti-tumor treatments.
28438506	0	23	Diacylglycerol Kinase ζ	T116,T123	C1743812
28438506	31	39	Cytokine	T116,T129	C0079189
28438506	51	60	Expansion	T043	C0007595
28438506	64	78	CD8(+) T Cells	T025	C0242629
28438506	90	108	Antitumor Capacity	T033	C0243095
28438506	109	122	Interleukin-2	T116,T129	C0021756
28438506	127	130	-15	T116,T129	C0254610
28438506	137	146	expansion	T043	C0007595
28438506	149	164	differentiation	T043	C0007589
28438506	168	192	cytotoxic CD8(+) T cells	T025	C0039195
28438506	220	247	antigen-independent killing	T043	C0599733
28438506	254	262	property	T080	C0871161
28438506	266	276	clinically	T080	C0205210
28438506	277	285	relevant	T080	C2347946
28438506	309	315	T cell	T025	C0242629
28438506	323	342	antitumor therapies	T061	C0087111
28438506	344	367	Diacylglycerol kinase α	T116,T126	C3815868
28438506	372	373	ζ	T116,T123	C1743812
28438506	375	379	DGKα	T116,T126	C3815868
28438506	382	383	ζ	T116,T123	C1743812
28438506	385	395	metabolize	T044	C1148560
28438506	400	414	diacylglycerol	T109,T121,T123	C0043791
28438506	435	454	antigen recognition	UnknownType	C0678894
28438506	458	471	T lymphocytes	T025	C0242629
28438506	482	492	expression	T045	C1171362
28438506	506	519	lipid kinases	T116,T126	C0113519
28438506	523	556	tumor-infiltrating CD8(+) T cells	T025	C0079722
28438506	568	588	hyporesponsive state	T169	C1442792
28438506	609	628	tumor immune escape	T046	C0282683
28438506	630	640	Inhibition	T039	C1524081
28438506	654	661	enzymes	T116,T126	C0014442
28438506	718	725	antigen	T129	C0003320
28438506	736	741	tumor	T191	C0027651
28438506	742	753	elimination	T058	C3178995
28438506	783	795	characterize	T052	C1880022
28438506	800	812	contribution	T052	C1880177
28438506	816	820	DGKα	T116,T126	C3815868
28438506	825	826	ζ	T116,T123	C1743812
28438506	830	837	antigen	T129	C0003320
28438506	851	860	cytotoxic	T169	C1511636
28438506	861	870	functions	T169	C0542341
28438506	874	888	CD8(+) T cells	T025	C0242629
28438506	890	898	Analysis	T062	C0936012
28438506	902	906	DGKζ	T116,T123	C1743812
28438506	909	918	deficient	T169	C0011155
28438506	919	923	mice	T015	C0025929
28438506	934	942	increase	T169	C0442805
28438506	946	962	bystander memory	T043	C0949629
28438506	969	994	CD8(+) T cell populations	T025	C0242629
28438506	1011	1015	DGKα	T116,T126	C3815868
28438506	1018	1027	deficient	T169	C0011155
28438506	1028	1032	mice	T015	C0025929
28438506	1054	1058	DGKζ	T116,T123	C1743812
28438506	1066	1084	cytokine responses	T043	C2247677
28438506	1091	1098	antigen	T129	C0003320
28438506	1112	1118	manner	T169	C0205245
28438506	1120	1128	Cytokine	T116,T129	C0079189
28438506	1139	1148	expansion	T043	C0007595
28438506	1152	1156	DGKζ	T116,T123	C1743812
28438506	1159	1168	deficient	T169	C0011155
28438506	1169	1183	CD8(+) T cells	T025	C0242629
28438506	1202	1217	differentiation	T043	C0007589
28438506	1221	1248	innate-like cytotoxic cells	T025	C0039195
28438506	1249	1257	in vitro	T080	C1533691
28438506	1295	1302	in vivo	T082	C1515655
28438506	1303	1323	anti-tumor responses	T033	C0243095
28438506	1327	1331	DGKζ	T116,T123	C1743812
28438506	1334	1343	deficient	T169	C0011155
28438506	1344	1348	mice	T015	C0025929
28438506	1368	1378	murine A20	T015	C0026809
28438506	1379	1387	lymphoma	T191	C0024299
28438506	1410	1417	isoform	T116	C0597298
28438506	1420	1428	specific	T080	C0205369
28438506	1429	1437	function	T169	C0542341
28438506	1442	1446	DGKζ	T116,T123	C1743812
28438506	1447	1457	downstream	T082	C0522506
28438506	1461	1465	IL-2	T116,T129	C0021756
28438506	1468	1473	IL-15	T116,T129	C0254610
28438506	1484	1493	expansion	T043	C0007595
28438506	1497	1526	innate-like cytotoxic T cells	T025	C0039195
28438506	1528	1543	Pharmacological	T169	C0205464
28438506	1544	1556	manipulation	T061	C0947647
28438506	1560	1564	DGKζ	T116,T123	C1743812
28438506	1565	1573	activity	T044	C0243102
28438506	1605	1613	cytokine	T116,T129	C0079189
28438506	1624	1645	anti-tumor treatments	T061	C0087111